13.58
-0.02(-0.15%)
Currency In USD
| Previous Close | 13.6 |
| Open | 13.5 |
| Day High | 13.76 |
| Day Low | 13.1 |
| 52-Week High | 18.17 |
| 52-Week Low | 5.9 |
| Volume | 30,524 |
| Average Volume | 20,573 |
| Market Cap | 116.39M |
| PE | -1.74 |
| EPS | -7.82 |
| Moving Average 50 Days | 12.11 |
| Moving Average 200 Days | 10.64 |
| Change | -0.02 |
If you invested $1000 in Surrozen, Inc. (SRZN) since IPO date, it would be worth $89.55 as of October 19, 2025 at a share price of $13.58. Whereas If you bought $1000 worth of Surrozen, Inc. (SRZN) shares 3 years ago, it would be worth $346.87 as of October 19, 2025 at a share price of $13.58.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Sep 04, 2025 8:15 PM GMT
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire Inc.
Aug 06, 2025 8:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and reg
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
GlobeNewswire Inc.
May 14, 2025 12:30 PM GMT
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements